Parties d'ouvrages collectifs (5)
  1. 1. Depondt, C. (2019). Familial Focal Epilepsy with Variable Foci. In The Causes of Epilepsy: Common and Uncommon Causes in Adults and Children (2 ed., pp. 171-174). Cambridge University Press.
  2. 2. Depondt, C. (2009). Pharmacogenetics in Neurological Diseases. In M. Ritsner (Ed.), Neuropsychiatric Biomarkers, Endophenotypes, and Genes. Willey Sciences.
  3. 3. Depondt, C. (2008). Pharmacogenomics applications in epilepsy. In N. Cohen (Ed.), Pharmacogenomics and Personalized Medicine. Humana Press.
  4. 4. Depondt, C. (2008). Epilepsies due to monogenic disorders of metabolism. In S. Shorvon & T. Pedley (Eds.), The Epilepsies. Elsevier.(Blue Books of Neurology).
  5. 5. Pandolfo, M., & Depondt, C. (2007). Friedreich's Ataxia and Related DNA Loss-of-Function Disorders. In Molecular Neurology (pp. 277-294). Elsevier Inc. doi:10.1016/B978-012369509-3.50020-2
    6.   Articles dans des revues avec comité de lecture (112)
  6. 1. Neuens, S., Soblet, J., Penninckx, A., Detry, C., Badoer, C., Desmyter, L., Peyrassol, X., Wilkin, F., Busson, A., Bruneau, M., Grenet, M.-L., Le Morillon, A., Aeby, A., Deconinck, N., Prigogine, C., Monier, A., Juvené, E., Balfroid, T., Van Hecke, A., Christiaens, F., Depondt, C., Brachet, C., Delvenne, V., Lufin, N., Bouysran, Y., Kammoun, M., Daneels, D., Caljon, B., Croes, D., Olsen, C., Van Dooren, S., Migeotte, I., Vandernoot, I., Marangoni, M., Coppens, S., Smits, G., & Vilain, C. (2025). Diagnostic yield of clinical exome sequencing in 868 children with neurodevelopmental disorders. European journal of medical genetics, 105030. doi:10.1016/j.ejmg.2025.105030
  7. 2. Damien, C., Torcida Sedano, N., Depondt, C., Legros, B., & Gaspard, N. (2025). Features affecting treatment decisions and outcome in refractory status epilepticus. Epilepsia. doi:10.1111/epi.18423
  8. 3. Demidov, G., Yaldiz, B., Garcia-Pelaez, J., de Boer, E., Schuermans, N., Van de Vondel, L., Paramonov, I., Johansson, L. F., Musacchia, F., Benetti, E., Bullich, G., Sablauskas, K., Beltran, S., Gilissen, C., Hoischen, A., Solve-RD Consortium,, Duerinckx, S., Ossowski, S., de Voer, R., Lohmann, K., Oliveira, C., Topf, A., Vissers, L. E. L. M. L., Laurie, S., Salmon, K., & Depondt, C. (2024). Comprehensive reanalysis for CNVs in ES data from unsolved rare disease cases results in new diagnoses. NPJ genomic medicine, 9(1), 49. doi:10.1038/s41525-024-00436-6
  9. 4. Costello, D., Matthews, E., Aurangzeb, S., Doran, E., Stack, J., Wesselingh, R., Dugan, P., Choi, H., Depondt, C., Devinsky, O. I., Doherty, C. P., Kwan, P., Monif, M., O'Brien, T. J., Sen, A., & Gaspard, N. (2024). Clinical outcomes among initial survivors of cryptogenic new-onset refractory status epilepsy (NORSE). Epilepsia. doi:10.1111/epi.17950
  10. 5. Boothman, I., Clayton, L. M. S., McCormack, M., Driscoll, A. M., Stevelink, R., Moloney, P., Krause, R., Kunz, W. W., Diehl, S., O'Brien, T., Sills, G., de Haan, G. J., Zara, F., Koeleman, B., Depondt, C., Marson, A. G., Stefansson, H., Stefansson, K., Craig, J., Johnson, M. R., Striano, P., Lerche, H., Furney, S., Delanty, N., Consortium EpiPGX,, Sisodiya, S. M., & Cavalleri, G. L. (2023). Testing for pharmacogenomic predictors of ppRNFL thinning in individuals exposed to vigabatrin. Frontiers in Neuroscience, 17, 1156362. doi:10.3389/fnins.2023.1156362
  11. 6. Tatillo, C., Legros, B., Depondt, C., Rikir, E., Naeije, G., Jodaitis, L., Ligot, N., & Gaspard, N. (2023). Prognostic value of early electrographic biomarkers of epileptogenesis in high-risk ischaemic stroke patients. European journal of neurology. doi:10.1111/ene.16074
  12. 7. ILAE, C. O. C. E., Depondt, C., et al. (2023). GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture. Nature genetics.
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 Suivant >>